Contract Win with Battelle

RNS Number : 5860K

Instem Life Science Systems plc

19 July 2011

 



19 July 2011

Embargoed for 07:00

Instem Life Science Systems plc

("Instem" or the "Company")

Contract Win

Battelle Places Order with Instem for Provantis Preclinical and submit-SEND Software Solutions

Instem Solutions to Automate Full Range of R&D Processes

Instem Life Science Systems plc (AIM: INS.L), a leading provider of software applications to the global early development healthcare market, announced today that Battelle has purchased its Provantis® and submit™ preclinical software solutions to automate processes within its preclinical facilities.

Battelle is the world's largest independent research and development organisation. Battelle's health and life science capabilities support development, delivery, testing, and evaluation of innovative solutions for the biotech, pharmaceutical, and agrochemical industries and government agencies. 

Provantis is a modern, fully integrated software system for single users and global organisations engaged in preclinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple or complex studies within a GLP or non-GLP environment, on-site or over the Web.

Part of the Centrus solution suite, Instem's submit™ software supports the US food and Drug Administration (FDA) sponsored Standard for Exchange of Nonclinical Data (SEND) initiative. Submit is the only fully integrated solution in production today for companies using SEND for the exchange, review and submission of research data. Converting data from any source system into SEND files, submit allows sponsors, contract research organizations and regulators to share, visualise and analyse study data more efficiently.

Phil Reason, CEO of Instem, commented, "We are delighted to have secured this contract with Battelle, the world's largest independent research and development organisation. This is a strong competitive win for Provantis and an excellent early win for our newly launched Centrus suite. We continue to win the majority of new business placed in the early development healthcare market and look to the future with confidence."

For further information, please contact:

Instem Life Science Systems plc	[phone]
Phil Reason, CEO
Jim McLauchlan, CFO
Brewin Dolphin	[phone]
Mark Brady
Sean Wyndham-Quin
Threadneedle Communications	[phone]
Caroline Evans-Jones
Fiona Conroy

About Battelle

As the world's largest, independent research and development organization, Battelle provides innovative solutions to the world's most pressing needs through its four global businesses:  Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.5 billion in global R&D annually through contract research, laboratory management and technology commercialization.  Headquartered in Columbus, Ohio, Battelle oversees 22,000 employees in more than 130 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security and a nuclear energy lab in the United Kingdom.
 

Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.

Learn more at www.battelle.org

About Instem Life Science Systems plc

Instem (AIM:INS.L) is a world-leading information solutions provider to the life sciences - accelerating drug and chemical development by increasing client productivity and enhancing the processes that lead to safer, more effective products. In addition to highly focused departmental and scientific solutions, Instem provides a range of business intelligence, planning, workflow management, document management and report compilation applications.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software. 

To learn more about Instem solutions and its mission, please visit www.instem.com.  

 

END

 

 

NRAXVLFFFDFBBBF